SEC Form 10-Q filed by Bicycle Therapeutics plc
$BCYC
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/8/2024 | $25.00 | Equal-Weight | Stephens |
| 9/6/2024 | $35.00 | Outperform | RBC Capital Mkts |
| 8/7/2024 | $33.00 → $28.00 | Buy → Neutral | B. Riley Securities |
| 9/11/2023 | Neutral → Buy | B. Riley Securities | |
| 8/31/2022 | Outperform | Cowen | |
| 7/28/2022 | $30.00 | Overweight | Barclays |
| 7/6/2022 | $60.00 | Buy | Canaccord Genuity |
| 4/13/2022 | $62.00 → $33.00 | Buy → Neutral | B. Riley Securities |
Bicycle Therapeutics plc (NASDAQ:BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Nov. 19, 2024, at 10:30 a.m. GMT. A live webcast of the fireside chat will be accessible from the Investor section of the company's website at www.bicycletherapeutics.com. A replay of the webcast will be archived and available following the event. About Bicycle Therapeutics Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, referred t
Bicycle Therapeutics plc (NASDAQ:BCYC), today announced that on November 1, 2024, the Compensation Committee of the company's Board of Directors granted to twelve new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 56,700 ordinary shares. These awards were made under Bicycle Therapeutics' 2024 Inducement Plan and approved by the Compensation Committee as an inducement material to the employees entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). Each option has an exercise price equal to $23.44 per share, Bicycle Therapeutics' closing trading price on October 31, 2024, and will vest over four years, w
Presented updated clinical results across oncology pipeline, including a 45% overall response rate (ORR) for zelenectide pevedotin monotherapy and a 45% ORR for BT5528 6.5 mg/m2 every two weeks monotherapy, both in metastatic urothelial cancer Progressed radiopharmaceuticals pipeline with first human imaging data validating the potential of MT1-MMP as a novel cancer target and outlined company strategy in this area Cash and cash equivalents of $890.9 million as of September 30, 2024, excluding $31.7 million UK R&D tax credit received in October 2024; expected financial runway into 2H 2027 Bicycle Therapeutics plc (NASDAQ:BCYC), a pharmaceutical company pioneering a new and differentiated
First human imaging data validate the potential of MT1-MMP as a novel target in the treatment of cancer and demonstrate positive properties of Bicycle Radionuclide Conjugates (BRC®) for radiopharmaceutical use Additional preclinical data demonstrate biodistribution of BRCs can be optimized to maintain high tumor uptake while significantly reducing kidney levels Company strategy focuses on pursuing novel targets using a range of isotopes to develop radiopharmaceuticals with first-in-class potential Bicycle Therapeutics to host conference call and webcast today at 8 a.m. ET Bicycle Therapeutics plc (NASDAQ:BCYC), a pharmaceutical company pioneering a new and differentiated class of therap
Company to host conference call and webcast on Wednesday, Oct. 23, at 8 a.m. ET to review the data and outline radiopharmaceuticals strategy Bicycle Therapeutics plc (NASDAQ:BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that the company will present data highlighting its potential to develop differentiated radiopharmaceutical molecules, called Bicycle Radionuclide Conjugates (BRC®), at the European Association of Nuclear Medicine (EANM) 2024 Congress taking place October 19-23 in Hamburg, Germany. The German Cancer Consortium (DKTK), part of a cooperative network wi
Alignment with U.S. FDA on design of Phase 2/3 registrational trial, to be initiated in 1Q 2024 Innovative study design allows for potential accelerated approval in untreated (first-line) and previously treated (second-line plus) metastatic bladder cancer Conference call and webcast today at 8 a.m. ET Bicycle Therapeutics (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the company will proceed with its plan to expedite development of BT8009 for metastatic bladder (urothelial) cancer following recent discussions with the U.S. Food and Drug Administration (FD
- SEC Filing
U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling more than 550 points on Thursday. The Dow traded down 1.44% to 39,098.81 while the NASDAQ fell 0.39% to 16,735.32. The S&P 500 also fell, dropping, 0.69% to 5,270.47. Check This Out: How To Earn $500 A Month From Ross Stores Stock Ahead Of Q1 Earnings Leading and Lagging SectorsInformation technology shares rose by 1.5% on Thursday. In trading on Thursday, real estate shares fell by 1.3%. Top Headline BJ's Wholesale Club Holdings, Inc. (NYSE:BJ) reported better-than-expected results for its first quarter on Thursday. The company posted quarterly revenue growth of 4.1% year-on-year to $4
U.S. stocks traded mixed midway through trading, with the Dow Jones index falling more than 250 points on Thursday. The Dow traded down 0.65% to 39,414.01 while the NASDAQ rose 0.84% to 16,942.51. The S&P 500 also rose, gaining, 0.24% to 5,319.63. Check This Out: How To Earn $500 A Month From Ross Stores Stock Ahead Of Q1 Earnings Leading and Lagging SectorsInformation technology shares rose by 1.3% on Thursday. In trading on Thursday, real estate shares fell by 1.1%. Top Headline The S&P Global manufacturing PMI rose to 50.9 in May from 50 in April, while services PMI climbed to 54.8 in May from 51.3. The S&P Global composite PMI jumped to 54.4 in May compared to 51.3
Stephens initiated coverage of Bicycle Therapeutics with a rating of Equal-Weight and set a new price target of $25.00
RBC Capital Mkts initiated coverage of Bicycle Therapeutics with a rating of Outperform and set a new price target of $35.00
B. Riley Securities downgraded Bicycle Therapeutics from Buy to Neutral and set a new price target of $28.00 from $33.00 previously
4 - BICYCLE THERAPEUTICS PLC (0001761612) (Issuer)
4 - BICYCLE THERAPEUTICS PLC (0001761612) (Issuer)
4 - BICYCLE THERAPEUTICS PLC (0001761612) (Issuer)
10-Q - BICYCLE THERAPEUTICS PLC (0001761612) (Filer)
8-K - BICYCLE THERAPEUTICS PLC (0001761612) (Filer)
8-K - BICYCLE THERAPEUTICS PLC (0001761612) (Filer)
SC 13G/A - BICYCLE THERAPEUTICS PLC (0001761612) (Subject)
SC 13G/A - BICYCLE THERAPEUTICS PLC (0001761612) (Subject)
SC 13G/A - BICYCLE THERAPEUTICS PLC (0001761612) (Subject)
EDINBURGH and CAMBRIDGE, United Kingdom, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Macomics Ltd, a leader in macrophage drug discovery, announces that it has appointed Kevin Lee Ph.D., MBA as Independent Non-Executive Director. Based in the UK and CEO of Cambridge, UK/Cambridge, US based, Bicycle Therapeutics (NASDAQ:BCYC), Kevin brings two decades of biotech and pharma experience to Macomics. In addition to his seat on Bicycle's board of directors, he is also a non-executive director of Alchemab Therapeutics Ltd. Kevin has led Bicycle Therapeutics since 2015, steering it through its strategic growth including various collaborations and financings including through its listing on NAS
Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the appointment of Alethia Young as its new Chief Financial Officer, effective July 17th. Ms. Young joins Bicycle from Graphite Bio, where she served as Chief Financial Officer, and previously served as senior biotech analyst and head of research at Cantor Fitzgerald. "We are thrilled to welcome Alethia to Bicycle and believe her experience and insights will make her an invaluable addition to our team," said Kevin Lee, Ph.D., Chief Executive Officer of Bicycle Therapeutics. "Alethia is a se
- Santiago Arroyo, M.D., Ph.D., appointed Chief Development Officer - Jennifer Perry, Pharm.D., promoted to Senior Vice President, Commercial Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the appointment of Santiago Arroyo, M.D., Ph.D., as Chief Development Officer, effective March 31. In addition, Jennifer Perry, PharmD, has been promoted to Senior Vice President, Commercial. Dr. Arroyo brings to Bicycle over 20 years of biopharmaceutical industry experience, leading the clinical development of therapeutics across multiple disease a